{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:08:51Z","timestamp":1789024131997,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00415-026-14045-z","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:49:35Z","timestamp":1785862175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-3548","authenticated-orcid":false,"given":"Vito A. G.","family":"Ricigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-2480","authenticated-orcid":false,"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-6237","authenticated-orcid":false,"given":"Anne Marie","family":"Guennoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-3529","authenticated-orcid":false,"given":"G.","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6744-4956","authenticated-orcid":false,"given":"J.","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8375-7530","authenticated-orcid":false,"given":"Marianne","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2363-9352","authenticated-orcid":false,"given":"Pierre","family":"Clavelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-8817","authenticated-orcid":false,"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-7578","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"2","key":"14045_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40120-022-00430-z","volume":"12","author":"J De S\u00e8ze","year":"2023","unstructured":"De S\u00e8ze J, Suchet L, Mekies C et al (2023) The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus. Neurol Ther 12(2):351\u2013369","journal-title":"Neurol Ther"},{"key":"14045_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001094","volume":"8","author":"M Eschborn","year":"2021","unstructured":"Eschborn M, Pawlitzki M, Wirth T et al (2021) Evaluation of age-dependent immune signatures in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8:e1094","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"14045_CR3","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u20133161","journal-title":"Brain"},{"issue":"10","key":"14045_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/13524585241266180","volume":"30","author":"L Prosperini","year":"2024","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Gasperini C (2024) Disability patterns in multiple sclerosis: a meta-analysis on RAW and PIRA in the real-world context. Mult Scler 30(10):1309\u20131321","journal-title":"Mult Scler"},{"issue":"9","key":"14045_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00415-025-13293-9","volume":"272","author":"M Filippi","year":"2025","unstructured":"Filippi M, Amato MP, Centonze D et al (2025) The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus. J Neurol 272(9):565","journal-title":"J Neurol"},{"issue":"6","key":"14045_CR6","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","volume":"271","author":"BA Singer","year":"2024","unstructured":"Singer BA, Feng J, Chiong-Rivero H (2024) Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol 271(6):3116\u20133130","journal-title":"J Neurol"},{"issue":"1","key":"14045_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78\u201388","journal-title":"Lancet Neurol"},{"issue":"10","key":"14045_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J et al (2025) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24(10):850\u2013865","journal-title":"Lancet Neurol"},{"issue":"4","key":"14045_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300415","volume":"19","author":"NB Lomer","year":"2024","unstructured":"Lomer NB, Asalemi KA, Saberi A, Sarlak K (2024) Predictors of multiple sclerosis progression: a systematic review of conventional magnetic resonance imaging studies. PLoS ONE 19(4):e0300415","journal-title":"PLoS ONE"},{"issue":"5","key":"14045_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein D, Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15(5):287\u2013300","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"14045_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00415-025-13173-2","volume":"272","author":"C Gasperini","year":"2025","unstructured":"Gasperini C, Centonze D, Conte A et al (2025) Personalized therapy in multiple sclerosis: an Italian Delphi consensus. J Neurol 272(6):428","journal-title":"J Neurol"},{"issue":"10","key":"14045_CR12","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382\u20135394","journal-title":"J Neurol"},{"issue":"2","key":"14045_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184\u2013191","journal-title":"JAMA Neurol"},{"issue":"1","key":"14045_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","volume":"16","author":"JD L\u00fcnemann","year":"2020","unstructured":"L\u00fcnemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H (2020) Immune reconstitution therapie: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16(1):56\u201362","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"14045_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40120-024-00589-7","volume":"13","author":"J Ciron","year":"2024","unstructured":"Ciron J, Bourre B, Castelnovo G et al (2024) Holistic, long-term management of people with relapsing multiple sclerosis with cladribine tablets: expert opinion from France. Neurol Ther 13(3):503\u2013518","journal-title":"Neurol Ther"},{"key":"14045_CR16","unstructured":"European Medicines Agency. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing. Available at https:\/\/www.ema.europa.eu\/en\/news\/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing (accessed June 2026)"},{"key":"14045_CR17","doi-asserted-by":"publisher","first-page":"175628642312110","DOI":"10.1177\/17562864231211077","volume":"16","author":"VE Teschner","year":"2023","unstructured":"Teschner VE, Fleck AK, Walter C et al (2023) Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response. Ther Adv Neurol Disord 16:17562864231211076","journal-title":"Ther Adv Neurol Disord"},{"key":"14045_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133967","volume":"14","author":"C Ruschil","year":"2023","unstructured":"Ruschil C, Gabernet G, Kemmerer CL et al (2023) Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients. Front Immunol 14:1133967","journal-title":"Front Immunol"},{"key":"14045_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1327672","volume":"15","author":"R Holm Hansen","year":"2024","unstructured":"Holm Hansen R, von Essen MR, Reith Mahler M, Cobanovic S, Sellebjerg F (2024) Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine. Front Immunol 15:1327672","journal-title":"Front Immunol"},{"key":"14045_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G et al (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 29:168\u2013174","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG et al (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416\u2013426","journal-title":"N Engl J Med"},{"issue":"12","key":"14045_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S et al (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594\u20131604","journal-title":"Mult Scler"},{"key":"14045_CR24","unstructured":"European Medicines Agency. Mavenclad. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad (accessed June 2026)."},{"key":"14045_CR25","doi-asserted-by":"publisher","first-page":"106107","DOI":"10.1016\/j.msard.2024.106107","volume":"92","author":"T Leist","year":"2024","unstructured":"Leist T, Yamout Y, Harlow D, Javor A (2024) Post-approval safety of cladribine tablets in the treatment of patients with multiple sclerosis: 2024 update. Mult Scler Relat Disord 92:106107","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR26","unstructured":"Leist T, Yamout B, Alexandri N, Chudecka A, Galazka A, Nolting A (2026) P416. Safety of cladribine tablets in the treatment of people with multiple sclerosis: 2025 post-approval safety update Abstract presented at the ACTRIMS Forum 2026, San Diego, CA, USA, February 5\u20137"},{"issue":"6","key":"14045_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/13524585231161494","volume":"29","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J et al (2023) Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study. Mult Scler 29(6):719\u2013730","journal-title":"Mult Scler"},{"issue":"15_supplement","key":"14045_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.1919","volume":"96","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Aydemir A, Verdun Di Cantogno E, Leist T (2021) CLASSIC-MS: long-term efficacy and real-world treatment patterns for patients with relapsing multiple sclerosis who received cladribine tablets in phase III parent trials (1919). Neurology 96(15_supplement):1919","journal-title":"Neurology"},{"key":"14045_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572","volume":"46","author":"T Leist","year":"2020","unstructured":"Leist T, Cook S, Comi G et al (2020) Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord 46:102572","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251351760","volume":"18","author":"K Schmierer","year":"2025","unstructured":"Schmierer K, Wiendl H, Barkhof F et al (2025) Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Ther Adv Neurol Disord 18:17562864251351760","journal-title":"Ther Adv Neurol Disord"},{"key":"14045_CR31","doi-asserted-by":"publisher","first-page":"106123","DOI":"10.1016\/j.msard.2024.106123","volume":"92","author":"N De Stefano","year":"2024","unstructured":"De Stefano N, Vermersch P, Wiendl H et al (2024) 162 Long-term effectiveness of cladribine tablets over 4 years in relapsing multiple sclerosis: results from the MAGNIFY-MS Extension Study. Mult Scler Relat Disord 92:106123","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"14045_CR32","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/13524585231205962","volume":"29","author":"B Brochet","year":"2023","unstructured":"Brochet B, Solari A, Lechner-Scott J et al (2023) Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study. Mult Scler 29(14):1808\u20131818","journal-title":"Mult Scler"},{"key":"14045_CR33","doi-asserted-by":"publisher","first-page":"106122","DOI":"10.1016\/j.msard.2024.106122","volume":"92","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Langdon D, Brochet B et al (2024) 161 Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study. Mult Scler Relat Disord 92:106122","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR34","unstructured":"Dukkipati R, Negroski D, Gutierrez A, Col\u00f3n BM, Maldonado VM, Chinea AR (2025) LBA06 - Efficacy and safety of cladribine tablets in a large US real-world multicenter population Abstract at the 2025 Annual Meeting of the Consortium of MS Centers, Phoenix, AZ, 28\u201331 May, 2025 Abstract available at https:\/\/cmsc.confex.com\/cmsc\/2025\/meetingapp.cgi\/Paper\/10484 (accessed June 2026)"},{"issue":"3S","key":"14045_CR35","first-page":"1268","volume":"31","author":"C Korsukewitz","year":"2025","unstructured":"Korsukewitz C, Richter N, Klehmet J, WagnerT CA, Poesevitz-Fejfar A (2025) Treatment continuation with cladribine tablets (CladT) beyond year 4\u2014second interim analysis of the CLIP-5 study. Mult Scler J 31(3S):1268","journal-title":"Mult Scler J"},{"key":"14045_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105704","volume":"88","author":"MC Kowarik","year":"2024","unstructured":"Kowarik MC, Ernst M, Woitschach L et al (2024) Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - results from a German cladribine cohort. Mult Scler Relat Disord 88:105704","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"14045_CR37","first-page":"405","volume":"31","author":"M Ernst","year":"2025","unstructured":"Ernst M, Cepek L, Kowarik M et al (2025) Retrospective analysis of multiple sclerosis patients who initiated oral cladribine 5\u20138 years ago\u2014Data from a German cladribine cohort. Mult Scler J 31(3):405","journal-title":"Mult Scler J"},{"issue":"3S","key":"14045_CR38","first-page":"1249","volume":"31","author":"D Kormann","year":"2025","unstructured":"Kormann D, Parekh M, von der Ma\u00dfen K et al (2025) Treatment continuation with cladribine tablets beyond year 4: analysis of longitudinal prescription data from Germany. Mult Scler J 31(3S):1249","journal-title":"Mult Scler J"},{"key":"14045_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106398","volume":"97","author":"C Kleinschnitz","year":"2025","unstructured":"Kleinschnitz C, Skuljec J, Kowarik MC et al (2025) First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions. Mult Scler Relat Disord 97:106398","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"14045_CR40","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/biomedicines13112590","volume":"13","author":"A Samara","year":"2025","unstructured":"Samara A, Ontaneda D (2025) Evolving the diagnosis of multiple sclerosis: a new landscape in light of the 2024 McDonald criteria. Biomedicines 13(11):2590","journal-title":"Biomedicines"},{"issue":"4","key":"14045_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00415-026-13753-w","volume":"273","author":"H Wiendl","year":"2026","unstructured":"Wiendl H, Gold R, Pul R et al (2026) Treatment-free remission in S: long-term disease control with cladribine tablets. J Neurol 273(4):218","journal-title":"J Neurol"},{"issue":"3","key":"14045_CR42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40120-026-00901-7","volume":"15","author":"A Chan","year":"2026","unstructured":"Chan A, Alroughani R, Calabrese M et al (2026) International expert opinion on optimal switching to cladribine tablets from other high-efficacy disease-modifying therapies for relapsing-remitting multiple sclerosis: opportunities and challenges. Neurol Ther 15(3):887\u2013906","journal-title":"Neurol Ther"},{"issue":"1","key":"14045_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/13524585211010294","volume":"28","author":"N De Stefano","year":"2022","unstructured":"De Stefano N, Sormani MP, Giovannoni G et al (2022) Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies. Mult Scler 28(1):111\u2013120","journal-title":"Mult Scler"},{"key":"14045_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103812","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skatteb\u00f8l L et al (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 62:103812","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"14045_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","volume":"83","author":"G Edan","year":"2023","unstructured":"Edan G, Le Page E (2023) Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients? Drugs 83(15):1351\u20131363","journal-title":"Drugs"},{"issue":"2","key":"14045_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00415-026-13704-5","volume":"273","author":"J Guo","year":"2026","unstructured":"Guo J, Olsson T, Alfredsson L, Hedstr\u00f6m AK (2026) Disability progression in multiple sclerosis: a latent class analysis of predictors. J Neurol 273(2):157","journal-title":"J Neurol"},{"issue":"8","key":"14045_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/WNL.0b013e31820d8b1d","volume":"76","author":"DT Okuda","year":"2011","unstructured":"Okuda DT, Mowry EM, Cree BA et al (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76(8):686\u2013692","journal-title":"Neurology"},{"issue":"11","key":"14045_CR48","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1177\/1352458519864933","volume":"26","author":"I Dekker","year":"2020","unstructured":"Dekker I, Sombekke MH, Balk LJ et al (2020) Infratentorial and spinal cord lesions: cumulative predictors of long-term disability? Mult Scler 26(11):1381\u20131391","journal-title":"Mult Scler"},{"issue":"4","key":"14045_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neurad.2020.01.083","volume":"47","author":"JC Brisset","year":"2020","unstructured":"Brisset JC, Kremer S, Hannoun S et al (2020) New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol 47(4):250\u2013258","journal-title":"J Neuroradiol"},{"issue":"2","key":"14045_CR50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/acn3.51969","volume":"11","author":"A Abdelhak","year":"2024","unstructured":"Abdelhak A, Antweiler K, Kowarik MC et al (2024) Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Ann Clin Transl Neurol 11(2):477\u2013485","journal-title":"Ann Clin Transl Neurol"},{"key":"14045_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106667","volume":"103","author":"S Mrabet","year":"2025","unstructured":"Mrabet S, Garcia EC, Giovannoni G (2025) Prediction of long-term outcome in multiple sclerosis: a systematic review. Mult Scler Relat Disord 103:106667","journal-title":"Mult Scler Relat Disord"},{"key":"14045_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231183221","volume":"16","author":"D Centonze","year":"2023","unstructured":"Centonze D, Amato MP, Brescia Morra V et al (2023) Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Ther Adv Neurol Disord 16:17562864231183221","journal-title":"Ther Adv Neurol Disord"},{"key":"14045_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101:104970","journal-title":"EBioMedicine"},{"issue":"10","key":"14045_CR54","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.3390\/ijms25105412","volume":"25","author":"G Maglio","year":"2024","unstructured":"Maglio G, D\u2019Agostino M, Caronte FP et al (2024) Multiple sclerosis: from the application of oligoclonal bands to novel potential biomarkers. Int J Mol Sci 25(10):5412","journal-title":"Int J Mol Sci"},{"key":"14045_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1442694","volume":"15","author":"X Jiang","year":"2024","unstructured":"Jiang X, Zhang H, Liu Y, Sun B, Mu G (2024) Global perspectives on the contribution of B cells to multiple sclerosis: an in-depth examination and evaluation. Front Immunol 15:1442694","journal-title":"Front Immunol"},{"issue":"2S","key":"14045_CR56","first-page":"91","volume":"31","author":"K Schmierer","year":"2025","unstructured":"Schmierer K, Vermersch P, Wiendl H et al (2025) Durable effects of cladribine tablets on CSF OCB and NfL over 4 years in relapsing multiple sclerosis: results from the MAGNIFY-MS Extension Study. Mult Scler J 31(2S):91","journal-title":"Mult Scler J"},{"issue":"3S","key":"14045_CR57","first-page":"701","volume":"31","author":"I Moreno Torres","year":"2025","unstructured":"Moreno Torres I, Costa-Frossard L, Meca-Lallana V et al (2025) Neurofilament light chain profile in cladribinetreated multiple sclerosis patients: implications for treatment monitoring. Mult Scler J 31(3S):701","journal-title":"Mult Scler J"},{"issue":"3S","key":"14045_CR58","first-page":"1082","volume":"31","author":"V Nicolella","year":"2025","unstructured":"Nicolella V, Cantone E, Varelli M et al (2025) Using plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis. Mult Scler J 31(3S):1082","journal-title":"Mult Scler J"},{"issue":"16","key":"14045_CR59","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","volume":"21","author":"SG Meuth","year":"2020","unstructured":"Meuth SG, Bayas A, Kallmann B et al (2020) Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother 21(16):1965\u20131969","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"14045_CR60","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","volume":"23","author":"SG Meuth","year":"2022","unstructured":"Meuth SG, Bayas A, Kallmann B et al (2022) Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother 23(13):1503\u20131510","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"14045_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","volume":"12","author":"M Habek","year":"2023","unstructured":"Habek M, Drulovic J, Brecl Jakob G et al (2023) Treatment with cladribine tablets beyond year 4: a position statement by southeast European multiple sclerosis centers. Neurol Ther 12(1):25\u201337","journal-title":"Neurol Ther"},{"issue":"2","key":"14045_CR62","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J (2022) Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther 11(2):571\u2013595","journal-title":"Neurol Ther"},{"issue":"4","key":"14045_CR63","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","volume":"11","author":"V Meca-Lallana","year":"2022","unstructured":"Meca-Lallana V, Garc\u00eda Dom\u00ednguez JM, L\u00f3pez Ruiz R et al (2022) Expert-agreed practical recommendations on the use of cladribine. Neurol Ther 11(4):1475\u20131488","journal-title":"Neurol Ther"},{"issue":"11","key":"14045_CR64","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1007\/s00415-023-11846-4","volume":"270","author":"P Petrou","year":"2023","unstructured":"Petrou P, Achiron A, Cohen EG et al (2023) Practical recommendations on treatment of multiple sclerosis with cladribine: an Israeli experts group viewpoint. J Neurol 270(11):5188\u20135195","journal-title":"J Neurol"},{"key":"14045_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106775","volume":"104","author":"R Alonso","year":"2025","unstructured":"Alonso R, Casas M, Rojas JI et al (2025) Progression independent of relapse activity (PIRA) in the era of high-efficacy treatments. Mult Scler Relat Disord 104:106775","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"14045_CR66","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra T, Copetti M, Zanetta C et al (2025) The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation. Neurol Neuroimmunol Neuroinflamm 12(4):e200415","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3S","key":"14045_CR67","first-page":"1203","volume":"31","author":"X Montalban","year":"2025","unstructured":"Montalban X, De Stefano N, Hodgkinson S et al (2025) Cladribine tablets show low 4-year PIRA Rates in MS: insights from pooled analyses of CLARIFY-MS and MAGNIFY-MS Studies. Mult Scler J 31(3S):1203","journal-title":"Mult Scler J"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14045-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14045-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14045-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:03:56Z","timestamp":1789023836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14045-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["14045"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14045-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VAGR has received personal\/consulting\/advisory board fees from Amgen, Novartis, Merck, Roche, Sanofi, Sandoz, Biogen, Janssen, M3 Global Research, Atheneum Partners, and unconditional research support from Roche and Juvise. JC has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Merck, Sanofi, Roche, Alexion and Amgen. BB serves on scientific advisory board, has received funding for travel and honoraria from Alexion, Amgen, Biogen, Juvise, Merck, Novartis, Sanofi and Roche. A-MG has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Merck, Sanofi, Roche. GC received fees for consulting and speaking from Biogen, Abbvie, Merck, Novartis, Roche, Sanofi Genzyme, Merz, Celgene BMS. PC has received honoraria, and contributions to meetings from Almirall, Biogen, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. JD and MP are employees of Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA. PV has received honorarium, contributions to meetings from Biogen, Sanofi-Genzyme, Novartis, Merck, Roche, AB Science, Janssen, Ad Scientiam and Juvis\u00e9 and Research supports from Novartis, Sanofi-Genzyme and Merck. JDS has received fees for consultancy, advisory board and clinical trials from UCB, Novartis, Biogen, Merck, Teva, Genzyme\/Sanofi, Roche, Alexion, BMS\/Celgene, Janssen, Horizon Therapeutics. XA has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Genzyme, Janssen, Juvise, Novartis, Merck, Roche and Sanofi.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article is based on previously conducted studies and the clinical expertise of the authors in treating pwMS. No new clinical studies were performed by the authors. No pwMS-specific efficacy or safety data were reported; therefore, institutional review board (IRB)\/ethics approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI-related technologies were used in the production of this article.","order":3,"name":"Ethics","label":"AI usage","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"507"}}